Data gathered: May 30
AI Stock Analysis - X4 Pharmaceuticals (XFOR)
Analysis generated May 30, 2025. Powered by Chat GPT.
X4 Pharmaceuticals is a leading biopharmaceutical company dedicated to the development and commercialization of novel therapeutics. The company's focus is primarily on treatments for rare diseases and conditions that lack adequate therapeutic options. They leverage their expertise in immunology and rare diseases to create innovative solutions, aiming to significantly impact the lives of patients. The company’s stock is publicly traded under the ticker symbol XFOR.
Stock Alerts - X4 Pharmaceuticals (XFOR)
 |
X4 Pharmaceuticals | May 29 Price is up by 8.3% in the last 24h. |
|
X4 Pharmaceuticals | May 27 Price is up by 10% in the last 24h. |
|
X4 Pharmaceuticals | May 22 Price is up by 12.3% in the last 24h. |
|
X4 Pharmaceuticals | May 21 Insider Alert: Baldry Mark is buying shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for X4 Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 89 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 94 | Sign up | Sign up | Sign up |
| Google Trends | 10 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 16 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,328 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,059 | Sign up | Sign up | Sign up |
| Twitter Mentions | 21 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 88 | Sign up | Sign up | Sign up |
| Linkedin Employees | 123 | Sign up | Sign up | Sign up |
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
| Price | $3.34 |
| Target Price | Sign up |
| Volume | 43,930 |
| Market Cap | $19M |
| Year Range | $2.71 - $24.24 |
| Dividend Yield | 0% |
| PE Ratio | 1.54 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 4% – Here’s What HappenedMay 26 - ETF Daily News |
 |
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA CongressMay 14 - Yahoo |
|
Equities Analysts Issue Forecasts for XFOR Q3 EarningsMay 5 - ETF Daily News |
|
X4 Pharmaceuticals (NASDAQ:XFOR) Price Target Raised to $7.00May 3 - ETF Daily News |
|
X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...May 1 - Yahoo |
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 29M | 4.7M | 24M | 280,000 | 3M | 0.040 |
| Q4 '24 | 1.4M | 300,000 | 1.1M | -40M | -37M | -0.200 |
| Q3 '24 | 560,000 | 230,000 | 330,000 | -37M | -34M | -0.180 |
| Q2 '24 | 560,000 | 270,000 | 300,000 | 91M | -34M | -0.070 |
| Q1 '24 | 0 | 62,000 | -62,000 | -52M | -50M | -0.260 |
Insider Transactions View All
| Baldry Mark filed to buy 25,337 shares at $2.5. May 20 '25 |
| Arbet-Engels Christophe filed to sell 14,207 shares at $0.5. January 27 '25 |
| DiBiase Mary filed to sell 490,980 shares at $0.5. January 27 '25 |
| Baldry Mark filed to sell 94,123 shares at $0.5. January 27 '25 |
Similar companies
Read more about X4 Pharmaceuticals (XFOR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of X4 Pharmaceuticals?
The Market Cap of X4 Pharmaceuticals is $19M.
What is X4 Pharmaceuticals' PE Ratio?
As of today, X4 Pharmaceuticals' PE (Price to Earnings) ratio is 1.54.
What is the current stock price of X4 Pharmaceuticals?
Currently, the price of one share of X4 Pharmaceuticals stock is $3.34.
How can I analyze the XFOR stock price chart for investment decisions?
The XFOR stock price chart above provides a comprehensive visual representation of X4 Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling X4 Pharmaceuticals shares. Our platform offers an up-to-date XFOR stock price chart, along with technical data analysis and alternative data insights.
Does XFOR offer dividends to its shareholders?
As of our latest update, X4 Pharmaceuticals (XFOR) does not offer dividends to its shareholders. Investors interested in X4 Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of X4 Pharmaceuticals?
Some of the similar stocks of X4 Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.